The pharmacokinetics of tinidazole after infusion (800 mg in 15 min) were studied in 12 patients with chronic renal failure (RI) and in five patients undergoing regular dialysis treatment (RD). Tinidazole elimination plasma half-life was 15.09 +/- 0.68 h (mean +/- s.e. mean) (RI) and 12.9 +/- 1.0 h after dialysis (RD), but there was a significant decrease in half-life during dialysis (4.25 +/- 0.43 h) P less than 0.001). The apparent volume of distribution (0.64 +/- 0.03 l/kg) was equal to extra and intracellular water volume and tinidazole was little bound to plasma protein (8%). There was a slight sex difference in apparent volume of distribution between male patients (0.70 +/- 0.09 l/kg) and female patients (0.59 +/- 0.10 l/kg) (P = 0.07), but as body clearance decreases in the same order, there was no modification of plasma half-life. In renal failure, pharmacokinetics of tinidazole were not disturbed because no correlation between half-life, body clearance and creatinine clearance occurred; urine elimination was about 7% of administered dose. Plasma clearance during dialysis was 49.9 +/- 3.2 ml/min and about 43% of the available drug was eliminated during the 6 h dialysis procedure. These results suggest that an additional half-dose infusion should be given after the end of dialysis in patients undergoing regular dialysis treatment.
展开▼
机译：在12例慢性肾衰竭（RI）和5例接受常规透析治疗（RD）的患者中研究了替硝唑在输注后的药代动力学（15分钟内800 mg）。替硝唑消除后血浆半衰期为15.09 +/- 0.68 h（平均+/-平均值）（RI）和透析后（RD）的12.9 +/- 1.0 h，但透析期间的半衰期显着降低（ 4.25 +/- 0.43 h）P小于0.001）。表观分布体积（0.64 +/- 0.03 l / kg）等于多余的和细胞内水的体积，替硝唑几乎不与血浆蛋白结合（8％）。男性患者（0.70 +/- 0.09 l / kg）和女性患者（0.59 +/- 0.10 l / kg）之间的表观分布体积略有性别差异（P = 0.07），但是随着体内清除率的降低同样的顺序，血浆半衰期没有改变。在肾衰竭中，替硝唑的药代动力学不受干扰，因为半衰期，身体清除率和肌酐清除率之间没有相关性。排尿量约为给药剂量的7％。透析过程中血浆清除率为49.9 +/- 3.2 ml / min，在6 h透析过程中消除了约43％的可用药物。这些结果表明，在接受常规透析治疗的患者中，应在透析结束后再进行半剂量输注。
展开▼
